Our results are concordant with the recently published results of patients with DLBCL treated with R-CHOP(like) in the FLYER trial, where a post hoc analysis comparing four cycles of R-CHOP + 2 × rituximab with a regimen of six cycles of R-CHOP in young and favorable DLBCL patients, and showed that four cycles of R-CHOP were associated with less BMD loss than patients receiving six cycles [25]. Here, DDIT3 is linked to diffuse large B-cell lymphoma.